Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SLC18A2 | Q05940 | 9/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304474 | 1.00 | HTR1A (0.61) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL1305173 | 0.91 | HTR2A (0.59) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL1305170 | 0.91 | HTR2A (0.59) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL1305695 | 0.90 | HTR1A (0.56) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL1305700 | 0.90 | HTR1A (0.56) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL13804910 | 0.84 | HTR1A (0.56) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL12111429 | 0.84 | HTR1A (0.56) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL12111430 | 0.83 | HTR2A (0.59) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL12111420 | 0.83 | HTR2A (0.59) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL12111627 | 0.83 | SLC18A2 (0.65) | KCNH2SLC18A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594568-A1 | Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes | General Electric Company (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594568-A1 | Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes | General Electric Company (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8053578-B2 | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes | GENERAL ELECTRIC COMPANY (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053578-B2 | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes | GENERAL ELECTRIC COMPANY (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053578-B2 | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes | GENERAL ELECTRIC COMPANY (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2217599-A1 | ALPHA-FLUOROALKYL TETRABENAZINE AND DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | General Electric Company (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009070552-A1 | ALPHA-FLUOROALKYL TETRABENAZINE AND DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | GENERAL ELECTRIC COMPANY (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070552-A1 | ALPHA-FLUOROALKYL TETRABENAZINE AND DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | GENERAL ELECTRIC COMPANY (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090142276-A1 | ALPHA-FLUOROALKYL DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | GENERAL ELECTRIC COMPANY (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090142276-A1 | ALPHA-FLUOROALKYL DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | GENERAL ELECTRIC COMPANY (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090142276-A1 | ALPHA-FLUOROALKYL DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | GENERAL ELECTRIC COMPANY (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142276-A1 | ALPHA-FLUOROALKYL DIHYDROTETRABENAZINE IMAGING AGENTS AND PROBES | CPT1A, DHCR24, VDAC1 | HTR1A 809/4885TBXA2R 1666/4885PTGS1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.